首页> 外文期刊>International Journal of Nanomedicine >Acute and subacute toxicity profiles of thymoquinone-loaded nanostructured lipid carrier in BALB/c mice
【24h】

Acute and subacute toxicity profiles of thymoquinone-loaded nanostructured lipid carrier in BALB/c mice

机译:载有甲状腺醌的纳米结构脂质载体在BALB / c小鼠中的急性和亚急性毒性谱

获取原文
           

摘要

Background: Thymoquinone (TQ), the predominant active lipophilic component in Nigella sativa seed oil, has a variety of pharmacological properties such as anticancer activities. However, translation of TQ to clinical phase is still not possible due to its hydrophobic properties. This problem can be solved by encapsulating it in nanoformulations to enhance its pharmacological properties. In our previous study, TQ has been successfully encapsulated in a nanostructured lipid carrier (hereinafter referred to as TQNLC) with excellent physiochemical properties such as high encapsulation efficiency, high drug-loading capacity, particle diameter less than 100?nm, and stability up to 2?years. In vitro studies also proved that TQNLC exhibited antiproliferative activity toward breast and cervical cancer cell lines. However, no toxicity profile related to this formulation has been reported. In this study, we determine and compare the in vivo toxicity of both TQNLC and TQ. Materials and methods: The in vivo toxicity (acute and subacute toxicity) study was carried out by oral administration of TQNLC and TQ to BALB/c mice. Animal survival, body weight, organ weight-to-body weight ratio, hematological profile, biochemistry profile, and histopathological changes were analyzed. Results: In acute toxicity, TQ that is loaded in nanostructured lipid carrier (NLC) was found to be less toxic than pure TQ. It can be concluded that encapsulation of TQ in lipid carrier minimizes the toxicity of the compound. In the subacute toxicity study, oral administration of 100?mg/kg of TQNLC and TQ did not cause mortality to either male or female but resulted in toxicity to the liver. It is postulated that long-term consumption of TQNLC and TQ may cause toxicity to the liver but not to the extent of altering the functions of the organ. For both treatments, the no observed adverse effect level (NOAEL) was found to be 10?mg/kg/d for mice in both sexes. Conclusion: For long-term oral consumption, TQ and TQNLC at a dose of 10?mg/kg is safe in mice and does not exert any toxic effect. The results provide safety information of TQNLC, which would further help researchers in clinical use.
机译:背景:百里香(NQella sativa)种子油中主要的亲脂活性成分胸腺醌(TQ)具有多种药理特性,例如抗癌活性。但是,由于TQ具有疏水性,因此仍无法将其转化为临床阶段。可以通过将其封装在纳米制剂中以增强其药理特性来解决此问题。在我们先前的研究中,TQ已成功地封装在具有优异的理化特性(例如高封装效率,高载药量,粒径小于100?nm且稳定性高达100%)的纳米结构脂质载体(以下称为TQNLC)中。 2年。体外研究还证明,TQNLC对乳腺癌和子宫颈癌细胞系表现出抗增殖活性。然而,尚未报道与该制剂有关的毒性概况。在这项研究中,我们确定和比较TQNLC和TQ的体内毒性。材料和方法:体内毒性(急性和亚急性毒性)研究是通过对BALB / c小鼠口服TQNLC和TQ进行的。分析动物的存活,体重,器官重量与体重之比,血液学特征,生化特征和组织病理学变化。结果:在急性毒性中,发现装载在纳米结构脂质载体(NLC)中的TQ的毒性低于纯TQ。可以得出结论,将TQ封装在脂质载体中可最大程度地降低该化合物的毒性。在亚急性毒性研究中,口服100?mg / kg的TQNLC和TQ不会导致男性或女性死亡,但会导致肝脏毒性。假定长期服用TQNLC和TQ可能对肝脏产生毒性,但不会改变器官功能。对于这两种疗法,未发现对雌雄同体小鼠的不良反应水平(NOAEL)为10?mg / kg / d。结论:对于长期口服,TQ和TQNLC剂量为10?mg / kg对小鼠是安全的,并且没有任何毒性作用。结果提供了TQNLC的安全性信息,这将进一步帮助研究人员进行临床使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号